SCHEMBL30612666

SCHEMBL30612666

C[C@@H]1C[C@@H]1n1cc(C(N)=O)ccc1=O

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ BRPF1 P55201 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ HRH3 Q9Y5N1 2/20 0.34
▸ BRD9 Q9H8M2 1/20 0.34
▸ PARP10 Q53GL7 3/20 0.33
▸ OPRK1 P41145 3/20 0.33
▸ OPRM1 P35372 3/20 0.33
▸ PARP1 P09874 2/20 0.33
▸ F2 P00734 1/20 0.33
▸ PARP15 Q460N3 1/20 0.33
▸ OPRD1 P41143 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ PARP2 Q9UGN5 1/20 0.33
▸ PARP4 Q9UKK3 1/20 0.33
▸ HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30612659 1.00 BRD4 (0.35) BRD4KDM4EALDH1A1BRPF1SMN1; SMN2
SCHEMBL30647145 0.75 BRD4 (0.35) BRD4KDM4EALDH1A1BRPF1SMN1; SMN2
SCHEMBL29092183 0.75 BRD4 (0.35) BRD4KDM4EALDH1A1BRPF1SMN1; SMN2
SCHEMBL30647220 0.75 BRD4 (0.35) BRD4KDM4EALDH1A1BRPF1SMN1; SMN2
SCHEMBL709323 0.70 BRD4 (0.47) BRD4KDM4EALDH1A1BRPF1SMN1; SMN2
SCHEMBL28300808 0.70 BRD4 (0.47) BRD4KDM4EALDH1A1BRPF1SMN1; SMN2
SCHEMBL924794 0.67 USP2 (0.40) KDM4EALDH1A1HSD17B10
SCHEMBL23805183 0.66 KDM4E (0.42) BRD4KDM4EALDH1A1BRPF1SMN1; SMN2
SCHEMBL28251574 0.66 PARP10 (0.42) BRD4KDM4EALDH1A1BRPF1SMN1; SMN2
SCHEMBL30601124 0.65 CHRNB2 (0.35) KDM4EALDH1A1PARP10OPRK1PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348424-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. 2023-11-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348424-A1 HETEROCYCLIC COMPOUNDS AND METHODS OF USE APC, RCC2, CDC37 BRD4 1287/4885KDM4E 4187/4885ALDH1A1 2243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback